Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,410 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00405587 | Safety Study of PLX4032 in Patients With Solid Tumors | completed | Phase 1 | 109 | PlexxikonINDUSTRY | 2 | Aug 22, 2017 | clinicaltrials |
| NCT01143753 | A Study of RO5212054 (PLX3603) in Participants With BRAF V600-Mutated Advanced Solid Tumors | completed | Phase 1 | 45 | Hoffmann-La RocheINDUSTRY | 3 | Jul 28, 2017 | clinicaltrials |
| NCT00704639 |
| Chemoradiation Treatment for Head and Neck Cancer |
| completed |
| Phase 1 / Phase 2 |
| 60 |
| Trans Tasman Radiation Oncology GroupOTHER |
| 1 |
| Jul 12, 2017 |
| clinicaltrials |
| NCT00996671 | Phase I Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2256098 in Healthy Volunteers(FTIH) | completed | Phase 1 | 38 | GlaxoSmithKlineINDUSTRY | 1 | Jun 14, 2017 | clinicaltrials |
| NCT00058526 | A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer | completed | Phase 1 | 61 | GlaxoSmithKlineINDUSTRY | 5 | May 15, 2017 | clinicaltrials |
| NCT01138033 | Study of a Focal Adhesion Kinase Inhibitor in Subjects With Solid Tumors | completed | Phase 1 | 74 | GlaxoSmithKlineINDUSTRY | 3 | May 11, 2017 | clinicaltrials |
| NCT02727283 | A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation Study in Normal Healthy Volunteers | completed | Phase 1 | 16 | GlaxoSmithKlineINDUSTRY | 1 | May 8, 2017 | clinicaltrials |
| NCT01949532 | Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease | completed | Phase 1 | 26 | AmgenINDUSTRY | 3 | May 2, 2017 | clinicaltrials |
| NCT02369198 | MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC | completed | Phase 1 | 27 | Asbestos Diseases Research FoundationOTHER | 1 | Apr 7, 2017 | clinicaltrials |
| NCT01125800 | A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB | completed | Phase 1 / Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 6 | Mar 20, 2017 | clinicaltrials |
| NCT01406119 | An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors | completed | Phase 1 | 14 | AbbVie (prior sponsor, Abbott)INDUSTRY | 2 | Jan 27, 2017 | clinicaltrials |
| NCT01773408 | A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia | completed | Phase 1 | 122 | Hoffmann-La RocheINDUSTRY | 7 | Jan 25, 2017 | clinicaltrials |
| NCT00800436 | A Dose-Finding Study of Subcutaneous Herceptin (Trastuzumab) in Healthy Male Volunteers and Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Females | completed | Phase 1 | 66 | Hoffmann-La RocheINDUSTRY | 2 | Dec 16, 2016 | clinicaltrials |
| NCT00825149 | A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma(GAUDI) | completed | Phase 1 | 137 | Hoffmann-La RocheINDUSTRY | 6 | Nov 4, 2016 | clinicaltrials |
| NCT00930514 | A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma | completed | Phase 1 | 281 | Hoffmann-La RocheINDUSTRY | 22 | Nov 2, 2016 | clinicaltrials |
| NCT01462175 | A First-In-Human Study of RO5503781 in Participants With Advanced Malignancies Except Leukemia | completed | Phase 1 | 99 | Hoffmann-La RocheINDUSTRY | 5 | Nov 2, 2016 | clinicaltrials |
| NCT01493336 | A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid Tumours | completed | Phase 1 | 37 | Hoffmann-La RocheINDUSTRY | 3 | Nov 2, 2016 | clinicaltrials |
| NCT01522664 | A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma | completed | Phase 1 | 53 | Genentech, Inc.INDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT01851824 | A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy | completed | Phase 1 | 9 | Hoffmann-La RocheINDUSTRY | 9 | Nov 2, 2016 | clinicaltrials |
| NCT01519323 | BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations | terminated | Phase 1 | 6 | Hoffmann-La RocheINDUSTRY | 10 | Oct 10, 2016 | clinicaltrials |
| NCT02605356 | Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | BayerINDUSTRY | 11 | Oct 7, 2016 | clinicaltrials |
| NCT01986218 | Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 36 | Bristol-Myers SquibbINDUSTRY | 3 | Sep 15, 2016 | clinicaltrials |
| NCT01777776 | Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. | terminated | Phase 1 / Phase 2 | 28 | Array BioPharmaINDUSTRY | 4 | Sep 13, 2016 | clinicaltrials |
| NCT02895412 | Infection and Tumour Antigen Cellular Therapy(INTACT-WT1) | unknown | Phase 1 | 20 | University of SydneyOTHER | 1 | Sep 9, 2016 | clinicaltrials |
| NCT00499850 | Phase I FOLFOX Combination | completed | Phase 1 | 18 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 25, 2016 | clinicaltrials |
| NCT00560391 | Dasatinib in Combination With Revlimid (and Dexamethasone) | completed | Phase 1 | 35 | Bristol-Myers SquibbINDUSTRY | 3 | Aug 4, 2016 | clinicaltrials |
| NCT00091377 | Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 65 | MEI Pharma, Inc.INDUSTRY | 2 | Jul 14, 2016 | clinicaltrials |
| NCT01666977 | Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 36 | AmgenINDUSTRY | 6 | Jun 3, 2016 | clinicaltrials |
| NCT01773018 | Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors(HMPL-504) | completed | Phase 1 | 47 | Hutchison Medipharma LimitedINDUSTRY | 1 | Jun 1, 2016 | clinicaltrials |
| NCT01088984 | Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia | completed | Phase 1 / Phase 2 | 43 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 12 | May 23, 2016 | clinicaltrials |
| NCT01475006 | AMG 595 First-in-Human in Recurrent Gliomas | completed | Phase 1 | 32 | AmgenINDUSTRY | 2 | Apr 15, 2016 | clinicaltrials |
| NCT02234297 | Safety Study of BLZ-100 in Adult Subjects With Glioma Undergoing Surgery | completed | Phase 1 | 17 | Blaze Bioscience Inc.INDUSTRY | 2 | Apr 6, 2016 | clinicaltrials |
| NCT02221505 | Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia | terminated | Phase 1 | 3 | Novartis PharmaceuticalsINDUSTRY | 4 | Apr 5, 2016 | clinicaltrials |
| NCT02723071 | A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL) | completed | Phase 1 / Phase 2 | 48 | Hoffmann-La RocheINDUSTRY | 6 | Mar 30, 2016 | clinicaltrials |
| NCT00634088 | Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer | terminated | Phase 1 | 13 | R-PharmINDUSTRY | 3 | Mar 10, 2016 | clinicaltrials |
| NCT00546611 | The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s) | withdrawn | Phase 1 | 0 | PeplinINDUSTRY | 1 | Jan 28, 2016 | clinicaltrials |
| NCT01624493 | BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients | withdrawn | Phase 1 / Phase 2 | 0 | Hoosier Cancer Research NetworkOTHER | 3 | Dec 23, 2015 | clinicaltrials |
| NCT01211691 | Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF) | suspended | Phase 1 / Phase 2 | 120 | Humanigen, Inc.INDUSTRY | 2 | Nov 17, 2015 | clinicaltrials |
| NCT02189824 | Chemotherapy Followed by Infusion of Partially HLA Matched Unrelated Donor Cells for Patients With AML Who Are Ineligible for Stem Cell Transplantation(SCRAMBLE) | unknown | Phase 1 | 12 | University of SydneyOTHER | 1 | Nov 2, 2015 | clinicaltrials |
| NCT00560235 | Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors | completed | Phase 1 / Phase 2 | 138 | PfizerINDUSTRY | 11 | Oct 28, 2015 | clinicaltrials |
| NCT00932126 | This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors | terminated | Phase 1 | 35 | PfizerINDUSTRY | 2 | Oct 28, 2015 | clinicaltrials |
| NCT01121575 | A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer | completed | Phase 1 | 70 | PfizerINDUSTRY | 2 | Oct 28, 2015 | clinicaltrials |
| NCT01253681 | Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer | completed | Phase 1 | 27 | AmgenINDUSTRY | 3 | Oct 14, 2015 | clinicaltrials |
| NCT01632852 | A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission | completed | Phase 1 | 30 | CSL LimitedINDUSTRY | 2 | Oct 9, 2015 | clinicaltrials |
| NCT00770536 | AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR | completed | Phase 1 | 103 | AmgenINDUSTRY | 3 | Sep 29, 2015 | clinicaltrials |
| NCT00659893 | Safety and Toleration of PEP005 Topical Gel When Applied to a Treatment Area of up to 100cm2 | completed | Phase 1 | 64 | PeplinINDUSTRY | 2 | Sep 14, 2015 | clinicaltrials |
| NCT00792558 | Ascending Multiple-Dose Study of BMS-817378 in Subjects With Advanced Cancers | withdrawn | Phase 1 | 0 | Bristol-Myers SquibbINDUSTRY | 2 | Sep 1, 2015 | clinicaltrials |
| NCT01107418 | A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma | completed | Phase 1 | 52 | Hoffmann-La RocheINDUSTRY | 2 | Aug 26, 2015 | clinicaltrials |
| NCT00618722 | Phase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat(ATX-101) | completed | Phase 1 / Phase 2 | 85 | Kythera BiopharmaceuticalsINDUSTRY | 3 | Jul 14, 2015 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials